APHA Stock: Down 55% From Record High, Is Aphria a Buy Right Now?

Aphria’s recent pullback provides investors an opportunity to buy a quality growth stock at a lower multiple.

edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Stocks in the cannabis space continue to remain volatile in 2021. Canadian pot stocks were trading near record highs when the country legalized marijuana for recreational use back in October 2018. However, investor enthusiasm soon turned bearish as companies were impacted by a slew of structural issues, including lower-than-expected demand, mounting losses, a thriving black market, and high inventory levels.

The sell-off was further exacerbated amid the COVID-19 pandemic, as retail stores were closed, driving consumer spending significantly lower. In November 2020, several pot stocks gained momentum after Joe Biden won the presidential race south of the border, and investors were optimistic about marijuana legalization at the federal level in the U.S.

Shares of Aphria (TSX:APHA)(NASDAQ:APHA) were trading at $0.75 shortly after it went public in December 2014. It soared to $23 by January 2018 and then fell to a multi-year low of $3.15 last March. Aphria stock then touched a record high of $40.93 in February 2021 and has since lost 55% in market value to trade at its current price of $18.55.

Despite high volatility in stock prices, Aphria has returned over 2,000% in cumulative gains since its IPO. Let’s see if the recent pullback presents a buying opportunity for investors.

Aphria’s recent quarterly results were disappointing

In the fiscal third quarter of 2021, Aphria reported net sales of $153.6 million. This reflected a year-over-year increase of 6.4% compared to net sales of $144.4 million in the prior-year period. Comparatively, Bay Street expected Aphria to post sales of $166.2 million in the December quarter.

The company also reported an adjusted net loss of $47.9 million, or $0.15 per share, marking a significant deterioration compared to an adjusted net loss of $9.8 million, or $0.04 per share, in fiscal Q3 of 2020. Analysts forecast Aphria’s net loss at $0.04 in Q3 of fiscal 2021.

Aphria generates sales from distribution revenue derived from the company’s CC Pharma operations in Germany. It also sells recreational and medical marijuana products.

The company’s net cannabis sales fell 24% on a sequential basis to $51.7 million while distribution revenue fell 5% to $87.1 million in Q3. These declines were attributed to lockdowns in Canada and Germany as well as lower marijuana selling prices.

What’s next for investors?

While Aphria sales in Q3 were less than impressive, the company retained its pole position in Ontario and Alberta in terms of cannabis sales. It is also the second-largest pot seller in Quebec. Aphria managed to record $14.8 million in net sales from its alcoholic beverage business, and the company’s acquisition of craft beer maker Sweetwater Brewing will hold it in good stead in the long term to help it gain traction in this disruptive vertical.

Aphria has posted eight consecutive quarters of positive adjusted EBITDA, and in Q3 this figure rose to $12.7 million, which was similar to its prior-year period.

The most important driver of Aphria stock is its upcoming merger with Tilray, which will make the combined entity the largest cannabis company in the world. Both the companies already have a presence in the U.S. and can scale production once marijuana is legalized in the country. Aphria’s strong balance sheet and its ability to consistently post a positive EBITDA make it a top pick given the recent pullback.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »